Immutrin
Biotech · Healthcare
Immutrin Secures $87M Series A for ATTR Amyloidosis Antibodies
March 24, 2026$87M · Series A
UK biotech Immutrin raised $87 million in a Series A round to advance antibody therapies targeting protein aggregates in ATTR amyloidosis, a progressive heart disease. The funding, led by Frazier Life Sciences and F-Prime, supports clinical proof-of-concept for its lead candidate.
Lead Investors
Frazier Life SciencesF-Prime
Read the Full Story in Velocity
Get curated startup and tech news with new stories published daily, company insights, and real-time alerts.